Redcliffe Labs Appoints Rohit Jalan as Chief Investment Officer to Drive Growth and IPO Readiness

Redcliffe Labs, a purpose-driven diagnostics network with a pan-India presence, has appointed Rohit Jalan as its new Chief Investment Officer (CIO). In this key leadership role, Rohit will lead the company’s capital strategy, spearhead inorganic growth initiatives, and prepare the organisation for its IPO journey.

As CIO, he will oversee strategic mergers and acquisitions, manage pre-IPO fundraising, strengthen investor relations, and shape Redcliffe’s positioning in public markets. With more than two decades of experience in investment banking, M&A, and corporate development—alongside involvement in over ten successful public listings—Rohit brings deep strategic insight and financial expertise. His earlier role as Chief Business Officer – Inorganic saw him lead Redcliffe’s Series C funding round and execute multiple high-impact acquisitions nationwide.

This leadership transition marks an important step as Redcliffe Labs continues to expand its footprint and accelerate its mission of making quality diagnostics accessible to every Indian. Guided by a customer-first approach, the company remains committed to clinical excellence, technology-driven innovation, and purpose-led growth.

Rohit’s appointment comes at a time when Redcliffe is strengthening its position as a future-ready healthcare organisation—one that is not only expanding access to diagnostics but also redefining the experience to be more empathetic, outcome-focused, and aligned with the evolving healthcare needs of the nation.